Author of

• 29168

  +

  Mini Oral session II (ID 63)

  • Event: ELCC 2019
  • Type: Mini Oral session
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 4/11/2019, 16:40 - 17:40, Room C

  • 29169

    +

    189O - EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with multiple brain metastases (ID 234)

    16:40 - 17:40  |  Presenting Author(s): Tao Jiang
    • Abstract
    • Presentation
    • Slides

    Background
    

    Brain metastasis (BM) is the intractable disease in patients (Pts) with advanced non-small-cell lung cancer (NSCLC). Previous studies reported that EGFR-TKI plus bevacizumab (Ebe) could result in a significant prolongation of progression-free survival (PFS) than EGFR-TKI (E) alone. This study aimed to investigate whether Ebe could provide survival benefit than E alone in EGFR-mutant NSCLC Pts with BM.

    a9ded1e5ce5d75814730bb4caaf49419 Methods
    

    Pts with EGFR-mutant NSCLC and radiologically confirmed BM (number > 3) were included. Pts with liver or leptomeningeal metastases were excluded. Intracranial PFS (iPFS) was defined as the time from the date of initiation of 1^st treatment to the date of intracranial progression or death and was censored at the date of last tumor assessment (when carried out). Systemic PFS (sPFS) was defined as the time from the date of initiation of 1^st treatment to the date of systemic progression (except intracranial progression) or death and was censored at the date of last tumor assessment (when carried out).

    20c51b5f4e9aeb5334c90ff072e6f928 Results
    

    164 Pts were identified. 121 received E and 43 received Ebe as 1^st treatment. Response rate was marginally higher in Ebe group than that in monotherapy group (69.7% vs. 52.9%, P = 0.055). Ebe was associated with a significantly longer iPFS (13.5 vs. 7.3 m, P < 0.001) and sPFS (14.4 vs. 8.8 m, P < 0.001) than E monotherapy. Importantly, median OS was markedly longer in Ebe group than in E group (30.1 vs. 22.4 m, P < 0.001). Different types of EGFR-TKIs showed comparable efficacy when combined with bevacizumab. However, erlotinib was associated with a significantly longer iPFS but similar sPFS and OS when compared with gefitinb and icotinib monotherapy. Multivariate analysis revealed that addition of bevacizumab was independently associated with prolonged iPFS (HR = 0.45, P < 0.001), sPFS (HR = 0.47, P < 0.001) and OS (HR = 0.50, P < 0.001).

    fd69c5cf902969e6fb71d043085ddee6 Conclusions
    

    The current study indicated that Ebe demonstrated the prolonged survival benefit than E alone in EGFR-mutant NSCLC Pts with multiple BM. These findings suggest that this strategy should be further explored in large-scale, strictly designed clinical trials as a standard treatment option in this clinical scenario.

    b651e8a99c4375feb982b7c2cad376e9 Legal entity responsible for the study
    

    The authors.

    213f68309caaa4ccc14d5f99789640ad Funding
    

    Has not received any funding.

    682889d0a1d3b50267a69346a750433d Disclosure
    

    All authors have declared no conflicts of interest.

    cffcb1a185b2d7d5c44e9dc785b6bb25

    Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.